JY-1-106

05/16/2013 - "A preclinical human cancer xenograft model was used to test the efficacy of JY-1-106 in vivo. "
05/16/2013 - "Strong TUNEL signals in the tumor cells demonstrated the effectiveness of JY-1-106 in this animal model. "
05/16/2013 - "Finally, JY-1-106 was evaluated in a tumor-bearing nude mouse model, and was found to effectively repress tumor growth. "
05/16/2013 - "We also observed that JY-1-106 was a very effective agent in inducing apoptosis in metabolically stressed tumors. "
05/16/2013 - "JY-1-106 effectively induced cell death regardless of the Mcl-1 expression level in ABT-737 resistant solid tumor cells, whilst toxicity toward normal human endothelial cells was limited. "

05/01/2018 - "The present study used the triple-negative human breast cancer cell line, MDA-MB-231, to analyze the effects of the Bcl-xL/Mcl-1 synthetic inhibitor, JY-1-106, alone or in combination with retinoids on cell viability. "

05/01/2018 - "Furthermore, the results highlighted that JY-1-106 alone is able to positively influence the gene expression profile of p53 and RARα, providing a therapeutic advantage in human triple-negative breast cancer treatment."
05/01/2018 - "Therapeutic potential of Bcl-xL/Mcl-1 synthetic inhibitor JY-1-106 and retinoids for human triple-negative breast cancer treatment."

10/01/2014 - "Here we investigated the novel BH3 domain mimetic, JY-1-106, which antagonizes the anti-apoptotic BCL-2 family members B-cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1 (MCL-1) alone and in combination with retinoids including atRA, AM580 (RARα agonist), and SR11253 (RARγ antagonist). "

05/01/2018 - "The results revealed a synergistic effect in reducing cell viability primarily by using JY-1-106 with the selective RARγ antagonist SR11253, which induces massive autophagy and necrosis. "